Duncan Mckechnie Sells 1,541 Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Duncan Mckechnie sold 1,541 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $519.00, for a total transaction of $799,779.00. Following the sale, the executive vice president owned 11,001 shares in the company, valued at $5,709,519. This represents a 12.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vertex Pharmaceuticals Price Performance

Shares of VRTX opened at $498.43 on Thursday. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $533.67. The stock has a market cap of $126.50 billion, a PE ratio of 29.56, a price-to-earnings-growth ratio of 2.23 and a beta of 0.29. The firm has a fifty day moving average price of $454.55 and a 200 day moving average price of $457.86.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.24 by $0.23. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The company had revenue of $2.99 billion for the quarter, compared to analyst estimates of $2.99 billion. During the same quarter last year, the company posted $4.06 earnings per share. The business’s quarterly revenue was up 8.3% compared to the same quarter last year. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 17.02 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Brighton Jones LLC increased its stake in Vertex Pharmaceuticals by 15.0% in the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after buying an additional 579 shares during the period. Gamco Investors INC. ET AL acquired a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter worth $228,000. NewEdge Advisors LLC lifted its stake in shares of Vertex Pharmaceuticals by 9.0% in the 2nd quarter. NewEdge Advisors LLC now owns 11,929 shares of the pharmaceutical company’s stock worth $5,311,000 after acquiring an additional 986 shares during the period. ICW Investment Advisors LLC boosted its holdings in shares of Vertex Pharmaceuticals by 5.0% in the second quarter. ICW Investment Advisors LLC now owns 604 shares of the pharmaceutical company’s stock valued at $269,000 after acquiring an additional 29 shares in the last quarter. Finally, Diversify Advisory Services LLC boosted its holdings in shares of Vertex Pharmaceuticals by 26.3% in the second quarter. Diversify Advisory Services LLC now owns 7,291 shares of the pharmaceutical company’s stock valued at $3,246,000 after acquiring an additional 1,518 shares in the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: The Crinetics deal could broaden Vertex’s growth profile, giving it immediate revenue from PALSONIFY and adding Atumelnant, a Phase 3 asset in congenital adrenal hyperplasia. Vertex to Acquire Crinetics Pharmaceuticals
• Positive Sentiment: Analysts and market commentary continue to frame the acquisition as a strategic fit that strengthens Vertex’s rare-disease pipeline and supports longer-term revenue diversification. Vertex’s Crinetics Deal Balances Growth with Integration Risk
• Positive Sentiment: Several broker notes remain constructive on VRTX, including Citi and other firms reiterating bullish views after the deal announcement. Citi Remains a Buy on Vertex Pharmaceuticals (VRTX)
• Neutral Sentiment: Vertex also disclosed a pre-planned insider stock sale, but the transaction was made under a Rule 10b5-1 plan, so it is unlikely to be read as a fundamental warning sign. SEC filing for Ourania Tatsis
• Negative Sentiment: Some investors appear cautious about the size of the cash deal, integration execution, and whether Vertex is paying a full price, which may be putting pressure on the shares. Crinetics Pharmaceuticals Investor Alert

Analysts Set New Price Targets

VRTX has been the subject of a number of research reports. Truist Financial began coverage on Vertex Pharmaceuticals in a research note on Wednesday, May 27th. They issued a “buy” rating and a $542.00 price objective for the company. Royal Bank Of Canada raised their target price on shares of Vertex Pharmaceuticals from $543.00 to $570.00 and gave the stock an “outperform” rating in a research report on Tuesday. Wall Street Zen downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, June 28th. Maxim Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $575.00 price target for the company in a research note on Wednesday, March 18th. Finally, Canaccord Genuity Group lowered their price objective on shares of Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating on the stock in a research report on Tuesday, May 5th. Twenty-one equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $557.09.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.